Sanofi (NASDAQ:SNY) Cut to “Neutral” at Bank of America

Sanofi (NASDAQ:SNY) was downgraded by analysts at Bank of America from a “buy” rating to a “neutral” rating in a note issued to investors on Thursday, MarketBeat reports.

A number of other equities research analysts also recently commented on the stock. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Barclays lowered Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Finally, TD Cowen reissued a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Five research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $62.67.

Sanofi Stock Performance

Shares of Sanofi stock opened at $49.25 on Thursday. The business has a 50-day simple moving average of $47.84 and a 200-day simple moving average of $48.63. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.29 and a current ratio of 1.09. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a market cap of $120.12 billion, a PE ratio of 13.68, a P/E/G ratio of 1.26 and a beta of 0.45.

Institutional Trading of Sanofi

Several hedge funds and other institutional investors have recently made changes to their positions in SNY. Brighton Jones LLC lifted its position in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after purchasing an additional 1,869 shares during the period. AQR Capital Management LLC increased its position in Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after buying an additional 752 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after buying an additional 347 shares during the period. Finally, Ameritas Advisory Services LLC purchased a new stake in shares of Sanofi in the second quarter valued at approximately $28,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.